CD33 and acute myeloid leukemia: Aliperta and colleagues described a novel approach to immunotherapy for acute myeloid leukemia (AML) in which genetically modified human MSCs were utilized as autonomous factories for the production of anti-CD33-anti-CD3 bi-specific antibodies (MSCsanti-CD33-anti-CD3) [39].